Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin (P-HDFL-DI)
Gastric Cancer
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring Combination, Chemotherapy, Inoperable Gastric Cancer
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed gastric adenocarcinoma Measurable or evaluable disease No previous C/T Age 16 ~ 75 years Karnofsky Performance Status of 60% 4 weeks after R/T Adjuvant C/T: the last dosing of C/T 6 months before enrollment WBC >= 4,000, platelets >= 100K, Creatinine <= 1.5mg/dl and proteinuria <1+, normal serum bil, transaminase <= 3.5x ULN, TG > 70mg/dl Exclusion Criteria: CNS metastasis Patients receive concomitant anti-cancer C/T or R/T Patients who are pregnant and with an expected life expectancy less than 3 months Symptomatic heart disease, active infection, extensive liver disease, or liver cirrhosis
Sites / Locations
- Department of Oncology, National Taiwan University Hospital
Arms of the Study
Arm 1
Experimental
A, 2, III
Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL